Alnylam Pharmaceuticalsvs.Neurocrine Biosciences
ALNY vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals is about 2.0× larger than Neurocrine Biosciences by market cap; Neurocrine Biosciences trades at the lower P/E (22.0 vs 37.6); year to date, Neurocrine Biosciences leads (+7.9% vs −40.6%).
Side by side
| ALNY | NBIX | |
|---|---|---|
| Market cap | $30.4B | $15.5B |
| Price | $240.08 | $153.37 |
| Today | +1.7% | +0.2% |
| Return YTD | −40.6% | +7.9% |
| Return 1Y | −48.1% | +13.0% |
| P/E | 37.6 | 22.0 |
| P/S | 6.3 | 4.6 |
| P/B | 22.4 | 4.2 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →More ALNY & NBIX comparisons
Other head-to-heads in the Biotech & innovation segment.
See where ALNY and NBIX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →